Ross I Baker, Alison M Street and Kerry M Taylor
Med J Aust 2002; 176 (1): . || doi: 10.5694/j.1326-5377.2002.tb04252.x
Published online: 7 January 2002

With our increased understanding of the molecular mechanisms of haematological disorders, it has become possible to target therapy precisely to the underlying defect. Targeted therapy can increase safety and potency, while causing fewer side effects than standard treatment. "Smart" drugs and gene therapy have recently shown great promise in a wide range of malignant haematological and coagulation disorders.

  • 1 Haematology Department, Royal Perth Hospital, University of Western Australia, Perth, WA.
  • 2 Haematology Department, Alfred Hospital, Melbourne, VIC.
  • 3 Haematology Department, Mater Hospital, Brisbane, QLD.


  • 1. Goldman JM, Melo JV. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1084-1086.
  • 2. White GC. Gene therapy in haemophilia: clinical trials update. Thromb Haemost 2001; 86: 172-177.
  • 3. Schnipper LE, Strom TB. A magic bullet for cancer — how near and how far? N Engl J Med 2001; 345: 283-284.
  • 4. Rosenberg RD. Redesigning heparin. N Engl J Med 2001; 344: 673-675.
  • 5. Hirsh J. New anticoagulants. Am Heart J 2001; 142 (2 Suppl): S3-S8.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.